Form D · Pharmaceuticals
VISUM PHARMA, INC.
Stamford, CT · CIK 0001883978
Offering snapshot reported Sep 13, 2023 · SEC filing
- Reported sold
- $50K Offering amount: $300K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Sep 12, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 13, 2023 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Nov 2, 2021 | Initial | $1,200,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b, 4a5
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-492053
Source: Form D, filed Sep 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Costantino | Director |
| Alex Cuomo | Executive |
| William J Gedale | Director, Executive |
| Bernard Peperstraete | Director |
| Mark Smith | Executive |
| Peter Vanderklish | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
48 Gurley Road
Stamford, CT, 06902
Stamford, CT, 06902